Welcome to our dedicated page for L A M Y SEC filings (Ticker: LMMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exousia Bio, Inc. filings document the issuer formerly known as L A M Y, including public-company reporting status, late Form 10-Q notifications, and material-event disclosures. The filing record includes Form 12b-25 notices describing delayed quarterly reports and an 8-K covering a reorganization agreement, acquisition-related share issuance, capital-structure disclosure, and governance matters.
Regulatory disclosures for LMMY also identify the company as an emerging growth company and provide formal records for its corporate transition, operating and financial reporting obligations, and biotechnology-related clinical or regulatory disclosure categories.
Exousia Bio (still trading as L A M Y / LMMY) used this 10-Q to document a major pivot and ongoing financial strain. In November 2025 it acquired Exousia AI, a clinical-stage biotechnology company focused on exosome-based oncology therapies, by issuing 62,223,000 common shares.
For the six months ended November 30, 2025, the company reported no revenue and a net loss of $50,897, driven by $206,711 of operating expenses, including higher research and development and professional fees, partly offset by a $217,922 gain on the Exousia AI acquisition. Management discloses an accumulated deficit of $288,623 and explicitly raises substantial doubt about its ability to continue as a going concern without new capital.
As of November 30, 2025, 70,000,000 common shares were issued and outstanding, up from 7,777,000 at May 31, 2025, reflecting the reverse-merger structure. Subsequent events include authorizing preferred stock, changing the corporate name to Exousia Bio, cancelling 21,000,000 previously issued shares under a rescission agreement, issuing 3,500,000 shares to a consultant, and entering a $250,000 15% convertible note with GBII Partners Inc. that allows conversion at a significant discount to market, subject to a 4.999% beneficial ownership cap.
L A M Y reported that it has completed the acquisition of Exousia Ai, Inc., a Florida clinical-stage biotechnology company developing plant-based exosome therapies, by issuing 62,223,000 shares of its common stock to Exousia Ai’s two shareholders. Following the closing on November 17, 2025, Exousia Ai became a wholly owned subsidiary and Exousia Pro Holding Management, LLC now owns 41,223,000 shares, representing about 58.89% of L A M Y’s 70,000,000 shares outstanding as of that date, resulting in a change of control and a shift in strategy to exosome-based biotech, cosmeceutical and nutraceutical products. Matthew Dwyer replaced Zhang Shengwu as sole officer and director, and the combined company highlights that Exousia Ai has received FDA Orphan Drug Designation for an exosome-based treatment for glioblastoma, while cautioning that it is early-stage, loss-making, under-capitalized and faces significant competition and financing, regulatory and penny‑stock market risks.
LAMY filed its quarterly report for the three months ended August 31, 2025, showing it remains a development-stage company with no operating revenue. The company reported a net loss of $31,814 for the quarter, compared with a net loss of $3,911 in the same period of 2024, driven mainly by professional fees, OTC market fees, and advertising expenses. As of August 31, 2025, LAMY reported total assets of $0 and total liabilities of $35,314, all current and largely due to related-party advances, resulting in a stockholders’ deficit of $35,314. The accumulated deficit since inception reached $63,584, and management states there is substantial doubt about the company’s ability to continue as a going concern. LAMY has 7,777,000 common shares outstanding and plans to rely on equity and/or debt financing and continued related-party support to fund operations, with no committed financing arrangements in place.
LAMY (LMMY) filed its Form 10‑K for the year ended May 31, 2025. The company is a development-stage eLearning and gaming startup centered on its twoplus1® financial education platform.
Revenue was $3,750 versus $11,500 a year earlier, while net income was $51,395 compared to a net loss of $25,807 in 2024, driven by other income of $86,739. Operating expenses were $31,843 (up slightly from $28,076). Cash was $0 and total stockholders’ equity was $0 as of May 31, 2025.
The auditor issued a going concern opinion citing limited operations and an accumulated deficit of $(31,770). Management reported material weaknesses in internal control, including lack of segregation of duties and no audit committee. A change in control occurred on December 6, 2024, with Zhang Shengwu acquiring 5,250,000 shares (about 67.51%) for $335,910 and becoming sole director and CEO. Common shares outstanding were 7,777,000 as of October 17, 2025; the stock trades on OTC Markets with sporadic volume.